AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05219994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia Exposure
Description: 2 hours of hyperoxia exposure during OGTT
Study NCT05219994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normoxia Exposure
Description: 2 hours of normoxia exposure during OGTT
Study NCT01427725 — intervention group
Intervention type: DRUG
Intervention: Lipacreon
Description: This study was an observational study and no intervention was specified
Study NCT03921502 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gall bladder transmural drainage with LAMS
Description: Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
Study NCT03921502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gall bladder transmural drainage with LAMS
Description: Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be \*placed on it to generate the anastomosis between the aforementioned structures.
Study NCT00468559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Run In Esomeprazole
Description: Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
Study NCT00468559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Blind Esomeprazole
Description: Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
Study NCT00468559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double Blind Placebo
Description: Double Blind Placebo
Study NCT00621101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study NCT00621101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany
Description: administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
Study NCT03719417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unicompartmental Biologic Arthroplasty
Description: Unicompartmental Biologic Arthroplasty surgery.
Study NCT03719417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensive Biologic Arthroplasty
Description: Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
Study NCT00621101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study NCT03764176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional impressions
Description: In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery.
Study NCT03764176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital impressions
Description: Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery.
Study NCT04148664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation with Standard RF ablation settings
Description: Standard RF ablation settings (n=30):~Maximum 35W for 20-40 seconds, per operator standard.
Study NCT04148664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation with High Power Short Duration RF ablation settings
Description: High power short duration RF (n=30):~Maximum 50 Watts for 5-15 seconds, per operator standard.
Study NCT02033083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria
Study NCT02033083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dilapan-S
Study NCT00403767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
Study NCT00403767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
Study NCT04195594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nic's Keto Diet
Description: Participants will be instructed to follow Nic's keto diet plan for 140 days. They will be asked to not exceed 20 g of carbohydrates (up to 5% caloric intake) and to consume the remaining 70% of calories from fat sources and 25% from protein sources.
Study NCT00403767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for Rivaroxaban arm (Warfarin placebo)
Description: Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
Study NCT00403767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo for Warfarin arm (Rivaroxaban placebo)
Description: Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
Study NCT00666692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
Description: Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
Study NCT04449419 — intervention group
Intervention type: OTHER
Intervention: There is not intervention.
Description: There is not intervention
Study NCT00507936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 1 mg capsule BID throughout treatment period
Study NCT02850289 — intervention group
Intervention type: DRUG
Intervention: Pegylated interferon (PEG-INF) alfa-2a
Description: Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
Study NCT00507936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 2 mg capsule BID throughout treatment period
Study NCT00507936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-894
Description: ABT-894 4 mg capsule BID throughout treatment period
Study NCT00507936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule BID throughout the treatment period
Study NCT00507936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 60 mg QD throughout treatment period
Study NCT06397430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral nutrition supplements
Description: parenteral nutrition
Study NCT06397430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition supplements
Description: enteral nutrition
Study NCT06397430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixed nutrition supplements
Description: mixed nutrition
Study NCT02480738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training Apparatus
Description: CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.
Study NCT02480738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Training Apparatus
Description: CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process.
Study NCT02850289 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
Study NCT03553108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment A
Description: Olaparib Tablet 25 mg
Study NCT02937623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)
Description: Experimental dissolvable polymer strip containing Novamin (15% weight by weight\[w/w\] calcium sodium phosphosilicate).
Study NCT01056393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab 800mg Q2Weeks
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
Study NCT01056393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibalizumab 2000mg Q4Weeks
Description: Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
Study NCT01493245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNS020QD
Description: During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
Study NCT03553108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment B
Description: Olaparib Tablet 100 mg
Study NCT03553108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment C
Description: Olaparib Tablet 150 mg
Study NCT02199769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
Study NCT04328337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Infusion of Intralipid 20%
Study NCT03553108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Treatment D
Description: Olaparib Tablet 250 mg
Study NCT04328337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: saline 30 ml/hr for 12 hours through an IV
Study NCT01872559 — intervention group
Intervention type: OTHER
Intervention: 3D Sonography analysis
Description: Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
Study NCT00632489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
Study NCT00632489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
Study NCT00632489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib, 1000 mg PO daily will be added to this combination.
Study NCT05010343 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: carbon ion irradation
Description: All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle
Study NCT05010343 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Ion Irradiation With SIB
Description: All patients will receive carbon ion irradiation with 65.6 GyE in 16 fractions to the prostate with or without seminal vesicle, and with simultaneous integrated boost (SIB) to the gross tumor in the PSMA PET/CT and mpMRI
Study NCT03545477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel locomotion treatment: curved-walking training
Description: Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)
Study NCT03545477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard locomotion treatment: straight-walking training
Description: It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
Study NCT03545477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
Study NCT03545477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
Study NCT03984084 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04348253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Berger
Description: Treatment 1
Study NCT04348253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3LT
Description: Treatment 2
Study NCT03297424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX2853
Description: tablets
Study NCT03478904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Liquid
Description: Enzalutamide liquid formulation given orally (160mg)
Study NCT03478904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide Capsule
Description: Enzalutamide gel capsule (4X 40mg)
Study NCT00880204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESS-EMCH training
Description: The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET).
Study NCT02304692 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bone anchored hearing aid
Study NCT02304692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone anchored hearing aid
Study NCT01955408 — intervention group
Intervention type: OTHER
Intervention: Questionnaires, anticholinergic treatment, urodynamic study
Study NCT00647933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Subcutaneous Org 36286
Study NCT00647933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyndiol®
Description: Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
Study NCT00311389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00311389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005%/Timolol 0.005% ophthalmic solution
Description: Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study NCT00878683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silicone catheter boot
Description: silicone device using Dermabond
Study NCT01594775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon (Oxytocin) nasal spray
Description: two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Study NCT01594775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two-times daily self-administration of nasal spray containing placebo during five days after wounding.
Study NCT03718351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal endoscopic microsurgery
Description: a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
Study NCT03718351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic submucosal dissection
Description: an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.